



FIRST IMPRESSION


15 DEC 2023 15:11 - PRODUCTION 15 DEC 2023 15:13 - DISSEMINATION

INDUSTRIALS

BUY

KEY DATA Share Price (EUR) 1.85 Target Price (EUR) 5.30 Upside / Downside 186.5% Ticker LMIA GR Market Cap (EUR m) 23 Shares Outstanding (m) 12.35

SHARE PRICE PERFORMANCE (12M)



PRICE PERFORMANCE TABLE

%	YTD	1M	3M	12M
Absolute	-53.2	1.1	-29.4	-53.8
Relative to SPI	-54.8	-2.8	-29.8	-53.7

All sources unless otherwise stated: Company data, FactSet, Mirabaud Securities. All data as of 14 December 2023

ANALYSTS

Daniel Koenig +41 58 816 88 72 daniel.koenig@mirabaud-msl.com

9M23 RESULTS: MORE CONCRETE FY24 SALES GUIDANCE. ANTICIPATING A GOOD 4Q23.

- 9M23 total revenues of EUR 30.2m, below the EUR 46.5m a year ago. Reasons: the pull-forward effect considering the takeover of the production from BMW, & the destocking during 1H23 before production ramped up in the new facility (May).
- **9M23 EBITDA reached break even** (EUR 0.1m) and improving EUR -0.04m at 1H23. Gross margin has achieved a sound 18.9%, above FY22 with 13.9%.
- Technology update: Further achievements with immersion cooling based on functional prototypes successfully tested by a large OEM.
- Management update: Appointment of a new CEO to be announced very soon.
 Board is in talks with an experienced candidate to guide the company through its next phase of growth and development.
- Increased focus on Investor Relations (IR) to strengthen relationship with investors. Examples of initiatives: reporting of group consolidated figures on a regular basis and the release of a new IR deck as of these 9M23 results; and a new IR website & CMD for 1Q24.
- FY guidance: Supported on very robust sales developments booked for 4Q23 so far (EUR 20m, c. 2x each of the previous quarters of the year) and considering the remaining shipments to be completed (EUR 5m), more specific guidance has been provided. From the previous range EUR 55-65m; to surpassing just over EUR 55m. Consequently, the new figure tilts to the lower end and is below our estimates that where at the midpoint (EUR 60m).
- Recommendation and target price. We will lower our FY23 revenues to converge with current guidance. We reiterate BUY recommendation and TP of EUR 5.3/share. 4Q23 seems to be a very strong quarter and should the trend continue, year 2024 could achieve very re-assuring figures.

EBITDA BREAKEVEN DILUTED BY HIGHER DDA AND FINANCIALS


For the 9M23 period LION has achieved EUR 30.2m of total revenues, with an EBITDA of EUR 0.1m and a **margin of 0.3%** which compares to -0.2% at 1H23. Also, on the positive, **other operating income has reached EUR 1.8m**, a substantial rise vs. FY22 at EUR 0.3m. Regarding the main cost items: **materials remain with a pretty stable** weight, 81.1% sales (vs. 1H23 at 80.1%) while personnel costs have increased to 14.2% sales (vs. 13.8% at 1H23). Gross margin is attractive at 18.9% vs. our FY expectations at c. 14%.

Below the EBITDA line, an **increase in the DDA** associated to the new production facility has prevented EBIT from reaching beak even and has led to a negative EUR - 0.5m and EBIT margin of -1.7%, vs. -0.6% at 1H23. Even further down the income statement, **financial expenses have increased substantially** to EUR -1.0m (vs. EUR -0.1m FY22) leading to a **net loss of EUR -0.7m**, with a margin of -2.3%, slight improvement vs. -2.9% at 1H23. Other aspects to highlight are the **positive operating cash flow** (EUR 1.1m) for the three quarters in a row; and the **substantial investment cash outflow** of EUR 10.3m in the period.


Fiscal Year ending December 31

CAL ENDAR

SALES BREAKDOWN BY SEGMENT



OPERATING RESULT BREAKDOWN BY MARKET



■ Canada ■ Europe ex Germany ■ C	Germany ■ USA
----------------------------------	---------------

VALUATION (x)	FY 2021	FY 2022	FY 2023E	FY 2024E	FY 2025E
P/E	nm	nm	nm	nm	nm
P / E adjusted	nm	nm	nm	nm	nm
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%

INCOME STATEMENT (EUR m)	FY 2021	FY 2022	FY 2023E	FY 2024E	FY 2025E
Revenue	29	54	60	75	146
Gross profit	3	8	8	11	22
EBITDA	-1	-0	-0	1	3
EBIT	-2	-1	-1	-1	1
Pre-tax profit	-2	-1	-2	-2	-0
Income taxes	0	-0	0	0	0
Net income	-1	-1	-2	-2	-0
EPS (EUR)	-0.12	-0.07	-0.19	-0.16	-0.02
Adjusted EPS (EUR)	-0.12	-0.07	-0.19	-0.16	-0.02
Fully diluted EPS (EUR)	-0.12	-0.07	-0.19	-0.16	-0.02
DPS (EUR)	0.00	0.00	0.00	0.00	0.00
Payout ratio	0.00	0.00	0.00	0.00	0.00
Margins					
Gross profit	10.4%	13.9%	13.9%	14.4%	15.1%
EBITDA	-4.3%	-0.4%	-0.2%	0.7%	1.8%
EBIT	-5.8%	-1.1%	-2.2%	-0.9%	1.0%
Pre-tax profit	-5.3%	-1.2%	-3.9%	-2.6%	-0.2%
Tax rate	23.5%	24.6%	0.0%	0.0%	15.0%
Net income	-4.0%	-1.5%	-3.9%	-2.6%	-0.1%
Growth rates					
Revenue	67.7%	87.5%	11.0%	25.0%	94.3%
EBITDA	-43.4%	80.6%	40.2%	461.1%	412.8%
EBIT	-57.9%	63.5%	-112.1%	50.1%	324.7%
Net income	-11.2%	29.8%	-187.9%	15.9%	90.0%
EPS	-11.2%	43.0%	-187.9%	15.9%	90.0%

BALANCE SHEET (EUR m)	FY 2021	FY 2022	FY 2023E	FY 2024E	FY 2025E
Non-current assets	11	15	15	19	20
Current assets	7	15	10	12	21
Current liabilities	6	5	5	7	15
Long-term liabilities	1	2	0	0	0
Shareholders' equity	9	14	12	10	10
Net debt	1	7	7	13	16
Net debt / EBITDA (x)	-1.1	-29.0	-50.8	25.4	6.0

CASH FLOW (EUR m)	FY 2021	FY 2022	FY 2023E	FY 2024E	FY 2025E
Net income	-1	-1	-2	-2	-0
Depreciation & amortisation	0	0	1	1	1
Other operating cash flow	0	0	0	0	0
Change in working capital	1	-7	3	0	-2
Cash flow from operating activities	0	-8	1	-1	-1
Capex	0	-3	-2	-5	-2
Cash flow from investing activities	-0	-3	-2	-5	-2
Cash flow from financing activities	2	10	9	15	17
Change in cash	2	-1	9	9	14
FCF	0	0	0	0	0
FCF/sales	0.0%	0.0%	0.0%	0.0%	0.0%

Sources: FactSet, Company data, Mirabaud estimates

DISCLAIMER

RECOMMENDATIONS HISTORY

LION E-Mobility

Market Index: SPI

Date	Market	Stock	Target	Recommendation
	Index	Price	Price	
	Level	(EUR)	(EUR)	
23 Oct 2023	652	1.86	5.30	Buy

RATINGS, CERTIFICATION AND DISCLOSURE

RATINGS SYSTEM

BUY: The stock is expected to generate absolute positive price performance of over 10% during the next 12

months.

HOLD: The stock is expected to generate absolute price performance of between negative 10% and positive 10%

during the next 12 months.

SELL: The stock is expected to generate absolute negative price performance of over 10% during the next 12

months.

RISK QUALIFIER: Speculative: The stock bears significantly higher risk that typically cannot be valued by normal

fundamental criteria and investment in the stock may result in material loss.

The ratings are applicable to all research produced after 1st January 2016

INVESTMENT ANALYST CERTIFICATION

All research is issued under the regulatory oversight of Mirabaud Securities Limited.

Each Mirabaud Securities Limited Investment Analyst whose name appears as the author of this research report hereby certifies that the recommendations and opinions expressed in the research report accurately reflect the Investment Analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such Investment Analyst's coverage universe.

INVESTMENT RESEARCH DISCLOSURES

The following disclosures relate to this document: 1, 3 & 11

- 1. This is a commissioned or a non-independent research note/comment.
- 2. In the past 12 months Mirabaud Securities or its affiliates have had corporate Finance mandates or managed or co-managed a public offering of the relevant Issuer's securities or received compensation for Corporate Finance services from the Relevant Issuer, excluding acting as a corporate broker, on a retained basis, for the Relevant Issuer.
- 3. Mirabaud Securities expect to receive or intend to seek compensation for Corporate Finance services from this company in the next 6 months, excluding acting as a corporate broker, on a retained basis, for the Relevant Issuer.
- 4. The Investment Analyst or a member of the Investment Analyst's household has a long position in the shares or derivatives of the Relevant Issuer.
- 5. The Investment Analyst or a member of the Investment Analyst's household has a short position in the shares or derivatives of the Relevant Issuer.
- 6. At the date of production Mirabaud Securities or its affiliates have a net long position exceeding 0.5% of the issued share capital of the Relevant Issuer.
- 7. At the date of production Mirabaud Securities or its affiliates have a net short position exceeding 0.5% of the issued share capital of the Relevant Issuer.
- 8. As of the month end immediately preceding the date of publication of this report, or the prior month end if publication is within 10 days following a month end, Mirabaud Securities and/or its affiliates beneficially owned 5% or more of any class of common equity securities of the Relevant Issuer.
- 9. A senior executive or director of Mirabaud Securities, or a member of his / her household, is an officer, director, advisor, or board member of the Relevant Issuer and/or one of its subsidiaries.
- 10. Mirabaud Securities acts as corporate broker, on a retained basis, for the Relevant Issuer.
- 11. This research note has been seen by the relevant Issuer to review factual content only prior to publication.
- 12. Factual changes have been made by the relevant Issuer prior to the distribution of this note/comment.

The Investment Analysts who are responsible for the preparation of this research report are employed by Mirabaud Securities Limited, a securities broker-dealer. The Investment Analysts who are responsible for the preparation of this research report have received (or will receive) compensation linked to the general profits of Mirabaud Securities Limited.

Copies of the Mirabaud Securities Policy on the Management of Material Interests and Conflicts of Interest in Investment Research can be obtained from the Mirabaud Securities Compliance Department by emailing compliance@mirabaud-msl.com
For the valuation methodology and investment risks, please contact the primary analyst directly.

ISSUED BY MIRABAUD SECURITIES LIMITED, A LIMITED COMPANY AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY. A MEMBER OF THE LONDON STOCK EXCHANGE

© Mirabaud Securities Limited. All rights reserved. Any unauthorised use or distribution is strictly prohibited. This document has been prepared and issued by Mirabaud Securities Limited or its associated companies and has been approved for publication in the United Kingdom by Mirabaud Securities Limited, a limited company authorised and regulated by the Financial Conduct Authority (FCA) or via its branch in Spain called Mirabaud Securities Limited Sucursal en España, a third country branch whose conduct of business activities are regulated by the CNMV. Neither the information nor the opinions expressed in this document constitute or intend to be an offer, or a solicitation of an offer, to buy or sell relevant securities (i.e. securities mentioned herein and options, warrants, or rights to or interests in any such securities). The information and opinions contained in this document have been compiled from and based upon generally available information which Mirabaud Securities Limited believes to be reliable but the accuracy or completeness of which cannot be guaranteed. All comments and estimates given are statements of Mirabaud Securities Limited's or an associated company's opinion only and no express or implied representation or warranty is given or to be implied therefrom. All opinions expressed herein are subject to change without notice. This document does not take into account the specific investment objectives, financial status, attitude to risk or any other specific matters relevant to any person who receives this document and should therefore not be used in substitution for the exercise of judgment by such person. Neither Mirabaud Securities

Limited nor any associated company accepts any liability whatsoever for any direct or consequential loss arising from the use of its research publications save where such loss arises as a direct result of Mirabaud Securities Limited's or an associated company's negligence. They may not be reproduced, distributed or published by you for any purpose except with Mirabaud Securities Limited's express written permission. Mirabaud Securities Limited, an associated company, or their employees and officers may have a holding (long or short) in an investment which it knows will be the subject of a published research recommendation to clients. It may also have a consulting relationship with a company being reported on. Mirabaud Securities Limited or an associated company may also act as agent of its clients and may have or have undertaken transactions in investments covered by this document prior to your receipt of it. Additional information on the contents of this report is available on request. Mirabaud Securities Limited and its affiliates (collectively "Mirabaud Group companies" or "Group") may collect and use personal data that they receive by any means. Mirabaud Group companies will only use such data in accordance with the Group Privacy Policy, a copy of which can be found on the www.mirabaud.com website or on request by emailing msglobaldataprivacy@mirabaud-msl.com.

IN CANADA

This research report is not a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described in such research report in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This research report is not investment advice and is not tailored to the needs of the recipient. In Canada, the information is intended solely for distribution to Permitted Clients (as defined in National Instrument 31-103) with whom Mirabaud Securities Limited deals pursuant to the international dealer exemption. To the extent that the information references securities may not be conducted through Mirabaud Securities Limited.

IN THE UNITED KINGDOM

Distribution of research reports in the United Kingdom is governed by the FCA rules. Research reports are issued by Mirabaud Securities Limited or an associated company for private circulation to eligible counterparties, professional clients and professional advisers, ("its clients"), and specifically not to private or retail clients.

IN THE UNITED STATES

Mirabaud Securities Limited is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to major U.S. institutional investors only in reliance on the exemption from registration provided by Rule 15a-6 of the US Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC"). The Information being furnished is for distribution to "Major U.S. Institutional Investors" within the meaning of Rule 15a-6 of the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934.

The material contained herein are not for release, publication, or distribution, directly or indirectly, in whole or in part to persons within Australia or Japan or in any other jurisdiction, or to any other person, where to do so would constitute a violation of applicable law or regulation.